Show simple item record

dc.contributor.authorSchmaljohn, A.L.
dc.contributor.authorOrlandi, C.
dc.contributor.authorLewis, G.K.
dc.date.accessioned2019-08-05T17:00:31Z
dc.date.available2019-08-05T17:00:31Z
dc.date.issued2019
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85069451819&doi=10.3389%2ffimmu.2019.01602&partnerID=40&md5=ac10bee3b8a6b9a0a649787bfda68a35
dc.identifier.urihttp://hdl.handle.net/10713/10224
dc.description.abstractLongstanding discordances and enigmas persist as to the specificities and other properties of antibodies (Abs) most effective in preventing or limiting many viral infections in mammals; in turn, failure to decipher key complexities has added to headwinds for both Ab-based therapeutic approaches and rational vaccine design. More recently, experimental approaches have emerged—and continue to emerge—for discerning the functional role of Ab structure, especially the Fc portion of antibody, in combating viral infections in vivo. A wide range of in vitro measures of antibody activity, from neutralization to antibody-dependent cell mediated cytotoxicity (ADCC)—each of these terms representing only an operational notion defined by the particulars of a given assay—are poised for assignment of both relevance and reliability in forecasting outcomes of infection. Of the several emergent technical opportunities for clarity, attention here is drawn to three realms: the increasing array of known modifications that can be engineered into Abs to affect their in vivo activities; the improvement of murine models involving knockouts and knock-ins of host genes including Fc receptors; and the development of additional virological design tools to differentiate Abs that act primarily by inhibiting viral entry from antibodies that mainly target viral antigens (Ags) on cell surfaces. To illustrate some of the opportunities with either zoonotic (emerging, spillover) or ancient human-adapted viruses, we draw examples from a wide range of viruses that affect humans.en_US
dc.description.sponsorshipFunding for authors was provided by the following grants and contracts: NIAID/NIH P01AI120756; DOD HDTRA1-15-C-058; and Grant # OPP1017606, The Bill and Melinda Gates Foundation.en_US
dc.description.urihttps://doi.org/10.3389/fimmu.2019.01602en_US
dc.language.isoen-USen_US
dc.publisherFrontiers Media S.A.en_US
dc.relation.ispartofFrontiers in Immunology
dc.subjectADCCen_US
dc.subjectAnimal modelsen_US
dc.subjectAntibodyen_US
dc.subjectFcen_US
dc.subjectFcRen_US
dc.subjectNeutralizationen_US
dc.subjectVirusen_US
dc.titleDeciphering Fc-mediated Antiviral Antibody Functions in Animal Modelsen_US
dc.typearticleen_US
dc.identifier.doi10.3389/fimmu.2019.01602


This item appears in the following Collection(s)

Show simple item record